blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4251283

EP4251283 - METHODS AND COMPOSITION FOR TREATMENT OF IMMUNE-MEDIATED DISEASES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  01.09.2023
Database last updated on 13.07.2024
FormerThe international publication has been made
Status updated on  04.06.2022
Formerunknown
Status updated on  31.12.2021
Most recent event   Tooltip02.02.2024Change: Validation statespublished on 06.03.2024  [2024/10]
02.02.2024Change - extension statespublished on 06.03.2024  [2024/10]
Applicant(s)For all designated states
General Nanotherapeutics LLC
566 Latimer Rd.
Santa Monica, CA 90402 / US
[2023/40]
Inventor(s)01 / HORWITZ, David A
Santa Monica, California 90402 / US
 [2023/40]
Representative(s)Secerna LLP
The Old Fire Station
18 Clifford Street
York YO1 9RD / GB
[2023/40]
Application number, filing date21827765.523.11.2021
[2023/40]
WO2021US60612
Priority number, dateUS202063118863P27.11.2020         Original published format: US 202063118863 P
[2023/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022115474
Date:02.06.2022
Language:EN
[2022/22]
Type: A1 Application with search report 
No.:EP4251283
Date:04.10.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 02.06.2022 takes the place of the publication of the European patent application.
[2023/40]
Search report(s)International search report - published on:EP02.06.2022
ClassificationIPC:A61P37/02, A61K38/18, A61K38/20, A61K47/69, C07K16/28
[2023/40]
CPC:
C07K16/2806 (EP); A61K39/4621 (US); A61K38/1729 (US);
A61K38/1841 (EP,US); A61K38/2013 (EP,US); A61K39/46434 (US);
A61K47/6849 (EP); A61K47/6937 (EP); A61P37/02 (EP);
A61P37/06 (US); C07K16/2809 (EP); C07K16/2812 (EP);
C07K16/2818 (EP); A61K2039/505 (EP); A61K2039/5154 (US);
A61K2039/577 (US) (-)
C-Set:
A61K38/1841, A61K2300/00 (EP);
A61K38/2013, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/40]
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNG ZUR BEHANDLUNG VON IMMUNVERMITTELTEN ERKRANKUNGEN[2023/40]
English:METHODS AND COMPOSITION FOR TREATMENT OF IMMUNE-MEDIATED DISEASES[2023/40]
French:MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR L'IMMUNITÉ[2023/40]
Entry into regional phase12.06.2023National basic fee paid 
12.06.2023Designation fee(s) paid 
12.06.2023Examination fee paid 
Examination procedure12.06.2023Examination requested  [2023/40]
12.06.2023Date on which the examining division has become responsible
12.01.2024Amendment by applicant (claims and/or description)
Fees paidRenewal fee
29.09.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[IY]WO2013173076  (UNIV SOUTHERN CALIFORNIA [US], et al) [I] 7,9,14,27-29 * example 1; claims 26-27 * [Y] 7,9,14,27-29;
    [XDYI] - HORWITZ DAVID A. ET AL, "Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor [beta]", ARTHRITIS & RHEUMATOLOGY, US, vol. 71, no. 4, doi:10.1002/art.40773, ISSN 2326-5191, (20190305), pages 632 - 640, URL: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/art.40773, XP055895617 [XD] 1-6,8,10-12,15-25,30,31,37 * the whole document * [Y] 7,9,14,27-29 [I] 13,28,32-36,38

DOI:   http://dx.doi.org/10.1002/art.40773
 [A]  - GRAY J D ET AL, "Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-beta: contrasting effects of anti-CD2 and anti-CD3", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, (19980301), vol. 160, no. 5, ISSN 0022-1767, pages 2248 - 2254, XP002099413 [A] 1-38
 [A]  - DENIZ GUNNUR ET AL, "Regulatory NK Cells Suppress Antigen-Specific T Cell Responses", THE JOURNAL OF IMMUNOLOGY, US, vol. 180, no. 2, doi:10.4049/jimmunol.180.2.850, ISSN 0022-1767, (20080115), pages 850 - 857, URL: https://www.jimmunol.org/content/jimmunol/180/2/850.full.pdf, XP055898316 [A] 1-38

DOI:   http://dx.doi.org/10.4049/jimmunol.180.2.850
 [A]  - GRAY J D ET AL, "THE ROLE OF TRANSFORMING GROWTH FACTOR BETA IN THE GENERATION OF SUPPRESSION: AN INTERACTION BETWEEN CD8+ T AND NK CELLS", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (19941101), vol. 180, no. 5, doi:10.1084/JEM.180.5.1937, ISSN 0022-1007, pages 1937 - 1942, XP000961145 [A] 1-38

DOI:   http://dx.doi.org/10.1084/jem.180.5.1937
 [A]  - ZHENG SONG GUO ET AL, "CD4 + and CD8 + Regulatory T Cells Generated Ex Vivo with IL-2 and TGF-[beta] Suppress a Stimulatory Graft-versus-Host Disease with a Lupus-Like Syndrome", THE JOURNAL OF IMMUNOLOGY, US, vol. 172, no. 3, doi:10.4049/jimmunol.172.3.1531, ISSN 0022-1767, (20040201), pages 1531 - 1539, URL: https://www.jimmunol.org/content/jimmunol/172/3/1531.full.pdf, XP055895677 [A] 1-38

DOI:   http://dx.doi.org/10.4049/jimmunol.172.3.1531
 [AD]  - ZUMRUT HASAN E ET AL, "Ligand-guided selection of aptamers against T-cell Receptor-cluster of differentiation 3 (TCR-CD3) expressed on Jurkat.E6 cells", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, AMSTERDAM, NL, (20160809), vol. 512, doi:10.1016/J.AB.2016.08.007, ISSN 0003-2697, pages 1 - 7, XP029711380 [AD] 13,14

DOI:   http://dx.doi.org/10.1016/j.ab.2016.08.007
 [A]  - TAKAHASHI MAYUMI ET AL, "High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency", SCIENTIFIC REPORTS, vol. 6, no. 1, doi:10.1038/srep33697, (20160901), URL: http://www.nature.com/articles/srep33697, XP055777216 [A] 13

DOI:   http://dx.doi.org/10.1038/srep33697
 [XP]  - HORWITZ DAVID A. ET AL, "Anti-CD2 Antibody-Coated Nanoparticles Containing IL-2 Induce NK Cells That Protect Lupus Mice via a TGF-[beta]-Dependent Mechanism", FRONTIERS IN IMMUNOLOGY, (20201216), vol. 11, doi:10.3389/fimmu.2020.583338, XP055895719 [XP] 1-6,8,10-12,15-25,30,31,37 * the whole document *

DOI:   http://dx.doi.org/10.3389/fimmu.2020.583338
by applicantGB929406
 GB929401
 US3266987
 US3610795
 US4460563
 US4794000
 US4816567
 US5624821
 WO9958572
 US6194551
 WO2009046446
    - "Overview of the pathogenesis of systemic lupus erythematosus", FERRETTI AND LA CAVA, Systemic lupus erythematosus. Basic, applied and clinical aspects, Academic Press, (20160000), pages 55 - 62
    - WONG et al., Drugs Today (Barc, (20110000), vol. 47, pages 289 - 302
    - BURT et al., JAMA, (20060000), vol. 295, pages 527 - 35
    - GITELMAN et al., J Autoimmun, (20160000), vol. 71, pages 78 - 87
    - HUNTER et al., ACS Nano, (20140000), vol. 25, pages 2148 - 60
    - MALDONADO et al., Proc Natl Acad Sci USA, (20150000), vol. 112, pages 156 - 65
    - LOOK et al., J Clin Invest, (20130000), vol. 123, pages 1741 - 9
    - OTOMO et al., J Immunol, (20150000), vol. 195, pages 5533 - 7
    - MAEDA et al., J Clin Invest, (20180000), vol. 128, pages 3445 - 59
    - CLEMENTE-CASARES et al., Nature, (20160000), vol. 530, pages 434 - 40
    - LAN et al., J Mol Cell Biol, (20120000), vol. 4, pages 409 - 19
    - PARK et al., Mol Pharm, (20110000), vol. 8, pages 143 - 52
    - SAKAGUCHI S et al., lmmunol Rev, (20060000), vol. 212, pages 8 - 27
    - Proc Natl Acad Sci USA., (20080219), vol. 105, no. 7, pages 2586 - 2591
    - MORRISON et al., Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, pages 6851 - 6855
    - ANGAL et al., Mol. Immunol., (19930000), vol. 30, pages 105 - 08
    - HOLLINGER et al., Proc. Natl. Acad. Sci. U.S.A., (19930000), vol. 90, pages 6444 - 48
    - GRUBER et al., J. Immunol., (19940000), vol. 152, page 5368
    - YU B et al., Mol Membr Biol., (20100000), vol. 27, no. 7, pages 286 - 98
    - ZUMRUT HE et al., Ann Biochem, (20160000), vol. 512, pages 1 - 7
    - CHEN W et al., J Exp Med, (20030000), vol. 198, pages 1875 - 86
    - SPANGLER JB et al., J Immunol, (20180000), vol. 201, pages 2094 - 2106
    - WAN YFLAVELL R., Immunol. Rev., (20070000), vol. 220, pages 199 - 213
    - "NCBI", Database accession no. NG_016779.1
    - MORTARA L. et al., Front. Immunol., (20180000), vol. 9, page 2905
    - ARENAS-RAMIREZ N et al., Trends Immunol., (20150000), vol. 36, no. 12, pages 763 - 777
    - "GenBank", Database accession no. S77834.1
    - MALDONADO RA et al., Proc Nat Acad Sci, (20150000), vol. 112, pages 156 - 65
    - Datta SK Ann NY Acad Sci, (20030000), vol. 987, pages 79 - 90
    - HAHN BH, Arthritis Rheum, (20010000), vol. 44, pages 438 - 441
    - ROEP BO et al., Lancet, (20190000), vol. 7, pages 65 - 74
    - SELSTED ME et al., Nature Immunol, (20050000), vol. 6, pages 552 - 557
    - SYKES M, Transplantation, (20170000), vol. 101, pages 274 - 83
    - KOSIEWICZ MMALARD P, Immunologic Res., (20060000), vol. 30, pages 155 - 70
    - TONGAONKER P et al., Physical Genomics, (20190000), vol. 51, pages 657 - 67
    - OCHANDO et al., J Immunol, (20050000), vol. 174, pages 3247 - 7005
    - HAFLER et al., J Immunol, (19880000), vol. 141, pages 131 - 8
    - RIGBY et al., J Clin Invest, (20150000), vol. 125, pages 3285 - 96
    - MCHUGH et al., Biomaterials, (20150000), vol. 59, pages 172 - 81
    - HORWITZ, DA et al., Arthritis Rheumatol, (20190000), vol. 71, pages 632 - 640
    - DINESH et al., Autoimmun Rev, (20100000), vol. 9, pages 560 - 8
    - LA CAVAET et al., J Immunol, (20040000), vol. 173, pages 3542 - 8
    - LOURENGO et al., Proc Natl Acad Sci USA, (20160000), vol. 113, pages 10637 - 42
    - FERRERA et al., Arthritis Rheum, (20070000), vol. 56, pages 1945 - 53
    - VIA et al., Immunol Today, (19880000), vol. 9, pages 207 - 13
    - RUS et al., J Immunol, (19950000), vol. 155, pages 2396 - 406
    - SINGH et al., J Immunol, (20070000), vol. 178, pages 7649 - 57
    - SHARABI et al., J Immunol, (20080000), vol. 181, pages 3243 - 51
    - SCALAPINO et al., PLoS One, (20090000), vol. 24, page e6031
    - SUZUKI et al., J Immunol, (20120000), vol. 189, pages 2118 - 30
    - ZHANG et al., J Immunol, (20090000), vol. 183, pages 6346 - 58
    - HIROKAWA et al., J Exp Med, (19940000), vol. 180, page 1937
    - HORWITZ et al., Clin Immunol, (20130000), vol. 149, pages 450 - 63
    - LABOWSKY et al., Nanomedicine, (20150000), vol. 11, no. 1, pages 019 - 28
    - LABOWSKY et al., Chem Eng Sci, (20120000), vol. 74, pages 114 - 123
    - STEENBLOCK et al., J Biol Chem, (20110000), vol. 286, pages 34883 - 92
    - OHTSUTKAHORWITZ, J Immunol, (19980000), vol. 160, pages 2539 - 45
    - ZHENG SG et al., International Immunol, (20060000), vol. 18, pages 279 - 89
    - RASOOL R, Int. J. Organ Transplantation Med, (20150000), vol. 6, pages 8 - 13
 US19630631188
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.